Corporate GovernanceApr 30, 2026, 06:13 AM
SGMO Amends 10-K to Include Governance & Executive Comp Details
AI Summary
Sangamo Therapeutics, Inc. filed an Amendment No. 1 to its 2025 Form 10-K to include previously omitted information for Items 10 through 14 of Part III, covering Directors, Executive Officers, Corporate Governance, and Executive Compensation. This amendment was necessary because the definitive proxy statement containing this information will not be filed within 120 days of the fiscal year-end. The filing also includes updated Sarbanes-Oxley certifications.
Key Highlights
- SGMO filed Amendment No. 1 to its 10-K to include omitted Part III information.
- The amendment provides details on Directors, Executive Officers, and Corporate Governance.
- Executive compensation for 2025 and 2024 is now included.
- CEO Alexander D. Macrae's 2025 total compensation was $2,596,918.
- CDO Nathalie Dubois-Stringfellow's 2025 total compensation was $1,118,556.
- CLO Scott B. Willoughby's 2025 total compensation was $1,102,983.
- 2025 cash incentive compensation achieved 40% of corporate objectives.
- 2025 base salary increases and bonuses are deferred due to financial constraints.
- CEO Macrae voluntarily waived his $178,805 cash bonus for 2025.
Price Impact
More from SGMO